Table 4.

Treatment emergent adverse events reported by ≥2 patients in any dose level (safety analysis set)

Adverse Event	Placebo	AZD7594 58 μg	AZD7594 250 μg	AZD7594 800 μg
	N = 52	N = 34	N = 34	N = 34
	n (%)	n (%)	n (%)	n (%)
Patients with any AE	17 (32.69)	13 (38.24)	9 (26.47)	12 (35.29)
Nasopharyngitis	8 (15.38)	4 (11.76)	2 (5.88)	4 (11.76)
Headache	0 (0.00)	0 (0.00)	3 (8.82)	2 (5.88)
Gastroenteritis	0 (0.00)	3 (8.82)	0 (0.00)	0 (0.00)
Diarrhoea	0 (0.00)	0 (0.00)	0 (0.00)	3 (8.82)
Cough	1 (1.92)	2 (5.88)	0 (0.00)	0 (0.00)
Dyspnoea	2 (3.85)	0 (0.00)	0 (0.00)	0 (0.00)

MedRA version 18.1, AE adverse event